Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR...

Prof George Sledge - Stanford Health Care, Stanford, USA

CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )

Comment: CDK4/6 inhibitors in advanced breast cancer

Prof Nadia Harbeck - University of Munich, Munich, Germany

Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )

Immunotherapy added to chemotherapy improves pathological complete response in...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous...

Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea

ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma ( Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea )

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian...

Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA

VELIA/GOG-3005 trial: Veliparib for high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )

Nivolumab plus ipilimumab combination offers chemotherapy-free option for...

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

Comment: Immunotherapy combination for advanced NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Iberdomide in combination with dexamethasone for multiple myeloma

Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA

Iberdomide in combination with dexamethasone for multiple myeloma ( Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA )

What is the role of autologous stem cell transplant in multiple myeloma?

Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical...

What is the role of autologous stem cell transplant in multiple myeloma? ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

More from ecancer